Recruiting
Phase 2
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
About this study
Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis. ctDNA effectively identified patients with highest relapse risk. This trial aims to explore whether the combination of anlotinib, immunotherapy and capecitabine could improve the outcome of this subgroup of high relapse risk patients compared with investigator's choice of therapy.
- Condition
- Breast Cancer
- Tested
- Anlotinib ,, Benmelstobart, Capecitabine
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Who can join
- Age
- 18 to 70 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Maximum age: 70 years
- Eligible sex: Female
- Study condition: Breast Cancer
- Stage II-III breast cancer patients, excluding occult breast cancer, inflammatory breast cancer, metaplasia breast cancer
- TNBC patients. TNBC was defined as ER \<= 10%, PR \<=10%, HER 0-1, or HER2 2+ and FISH negative.
Where
1 site, 1 recruiting
Sun Yat-sen Memorial Hospital
Guangzhou, Guangodng, China
Potential match only. Final eligibility is determined by the study team.